SCHEMBL7141013

SCHEMBL7141013

Cc1cc2cc(CN)ccc2c(N)n1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 6/20 0.57
NOS3 P29474 3/20 0.41
NOS1 P29475 3/20 0.41
NOS2 P35228 2/20 0.41
CYP2A6 P11509 1/20 0.37
LOXL2 Q9Y4K0 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA3 P07451 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34
CA5A P35218 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
CA5B Q9Y2D0 1/20 0.34
NR4A2 P43354 1/20 0.34
TLR8 Q9NR97 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10274426 0.86 ALDH1A1 (0.46) ROCK1NOS3NOS1NOS2CYP2A6
SCHEMBL17253660 0.81 ROCK1 (0.38) ROCK1NOS3NOS1NOS2
SCHEMBL17221600 0.79 ROCK1 (0.57) ROCK1NOS3NOS1NOS2CYP2A6
SCHEMBL29787060 0.78 ROCK1 (0.53) ROCK1NOS3NOS1NOS2CYP2A6
SCHEMBL28583787 0.78 ROCK1 (0.53) ROCK1NOS3NOS1NOS2CYP2A6
SCHEMBL15676703 0.77 LMNA (0.47) NOS3NOS1NOS2CYP2A6NR4A2
SCHEMBL27592978 0.77 KDM4E (0.47) CYP2A6NR4A2
Hydrochloric Acid SCHEMBL3761973 0.76 KDM4E (0.46) CYP2A6NR4A2
SCHEMBL393406 0.74 HTT (0.43) NR4A2
SCHEMBL7142868 0.74 USP7 (0.37) NR4A2TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642253-B2 Thrombin inhibitors comprising an aminoisoquinoline group AKZO NOBEL N. V. (NL) 2003-11-04 US disclosed
CN-1441784-A Thrombin inhibitors comprising aminoisoquinoline group AKZO NOBEL NV (NL) 2003-09-10 CN disclosed
US-20030166579-A1 THROMBIN INHIBITORS COMPRISING AN AMINOISOQUINOLINE GROUP N.V. ORGANON (NL) 2003-09-04 US disclosed
WO-2002004423-A9 THROMBIN INHIBITORS COMPRISING AN AMINOISOQUINOLINE GROUP AKZO NOBEL NV (NL) 2003-05-15 WO disclosed
EP-1303491-A1 THROMBIN INHIBITORS COMPRISING AN AMINOISOQUINOLINE GROUP Akzo Nobel N.V. (NL) 2003-04-23 EP disclosed
WO-2002004423-A1 THROMBIN INHIBITORS COMPRISING AN AMINOISOQUINOLINE GROUP AKZO NOBEL N.V. (NL) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166579-A1 THROMBIN INHIBITORS COMPRISING AN AMINOISOQUINOLINE GROUP F2, TFPI, SERPINC1 ROCK1 346/4885NOS3 397/4885NOS1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.